Myriad Genetics Fiscal Fourth-Quarter 2018 Earnings Call

08/21/2018

# Forward Looking Statements

#### Forward Looking Statements

Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based on management's current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company's annual reports on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company's projections or forwardlooking statements.

#### Non-GAAP Financial Measures

In this presentation, the Company's financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. The Company's financial measures under GAAP include substantial one-time charges related to its acquisitions and ongoing amortization expense related to acquired intangible assets that will be recognized over the useful lives of the assets and charges related to executive severance. Management believes that presentation of operating results that excludes these items provides useful supplemental information to investors and facilitates the analysis of the Company's core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the Company's business. A link to reconciliation of the GAAP to non-GAAP financial guidance is provided above.

Financial Guidance	Fiscal Year 2019
GAAP diluted earnings per share	\$0.40 - \$0.45
Acquisition – amortization of intangible assets	\$0.80
Stock based compensation expense	\$0.30
One time expenses	\$0.20
Non-GAAP diluted earnings per share	\$1.70 - \$1.75

For additional information on GAAP to non-GAAP reconciliation see: <u>https://www.myriad.com/investors/gaap-to-nongaap-reconciliation/</u>

### FY 2018 Fourth-Quarter Financial Results


Significantly Exceeded Expectations

	4Q18 Actual Results	4Q17 Actual Results (restated)	YoY Change	FY18 Actual Results	FY18 Initial Guidance
Revenue (in mil.)	\$200.9	\$199.6	1%	\$772.6	\$750-\$770
GAAP EPS	\$0.18	\$0.18	0%	\$1.82	\$0.37-\$0.42
Adjusted EPS	\$0.38	\$0.29	31%	\$1.20	\$1.00-\$1.05

## Pioneering Science in Fiscal Year 2018


Multiple Significant Scientific Achievements

- Launch of riskScore: 4<sup>th</sup> epoch in hereditary cancer testing
- Genesight GUIDED study met Remission & Response endpoints
- BRACAnalysis CDx approved for metBC in U.S. and Japan
- Validated Vectra DA as 3X more predictive than any other DA test
- 70 presentations and 23 manuscripts



### **Review of Fiscal Year 2018**

New Product Sample Volume and Revenue Set New Records



#### New Product FY18 Revenue = \$212M

Product	YoY Growth
GeneSight	59%
Vectra DA	31%
Prolaris	73%
EndoPredict	16%

### Critical Success Factors to Achieving Strategic Goals

STRATEGIC GOALS

>10% Revenue Growth

**>30%** Operating Margin

7 Products >\$50M

>10% International Revenue

#### **CRITICAL SUCCESS FACTORS**

Build upon a solid hereditary cancer foundation

Grow new product volume

Expand reimbursement coverage for new products

Increase RNA kit revenue internationally

Improve profitability with Elevate 2020

### Solid Hereditary Cancer Foundation


Six Straight Quarters of YoY Volume Growth With Stable Pricing



- 6 sequential quarters with YoY volume growth
- 3 sequential quarters with stable pricing
- Launched riskScore in Sept.
- BRACAnalysis CDx approved for metBC in U.S. and Japan
- metBC volume up 13% sequentially in fourth quarter
- Revenue expected to increase nominally YoY in FY19
- Expanded indications for >120,000 patients per year


# Record GeneSight Ordering Physicians and Volume

Ordering Physicians Have Nearly Doubled in Last Two Years



Myriad Copyright © 2018 Myriad Genetics, Inc., all rights reserved. www.Myriad.com.

#### Advances in Reimbursement Coverage For New Products New Product Reimbursement 1.6B in Potential Revenue



- Signed eight payers for Prolaris representing 20M lives including a top 10 national payers
- Announced CareFirst<sup>®</sup> coverage for GeneSight
- Large employer with 30,000 employees to cover GeneSight
- Signed partnership with Kroger<sup>®</sup> to cover Vectra DA – in late stage discussions on GeneSight
- Coverage from 8 commercial payers on myPath Melanoma
- Received final LCD from Medicare for EndoPredict


## **International Developments**

Kit-Based Strategy With Restructuring to Global LDT Laboratory

- Revised NICE draft guidance document on breast cancer prognostics recommends EndoPredict as one of three diagnostic tests
- Received pre market approval for BRACAnalysis CDx in Japan for HER2- metastatic breast cancer = 15,000 patients per year
- Selling German clinic and closing Munich laboratory
- Shift LDT testing to single U.S. based laboratory
- Continue with kit manufacturing and laboratory in Cologne Germany

### Improve Profitability With Elevate 2020

Adjusted Operating Margin Improves 380BP Year-Over-Year





FY 2018 Fourth-Quarter Revenue By Product

(in millions)

Product	4Q18	4Q17 (Restated)	YoY Growth
Hereditary Cancer	\$126.8	\$143.5	(12%)
GeneSight	\$33.9	\$25.5	33%
Vectra DA	\$15.1	\$10.3	47%
Prolaris	\$7.0	\$3.0	133%
EndoPredict	\$2.8	\$2.0	40%
Other	\$2.0	\$2.7	(26%)
Total Molecular Diagnostic Revenue	\$187.7	\$187.0	0%
Pharmaceutical & Clinical Services	\$13.3	\$12.6	6%
Total Revenue	\$200.9	\$199.6	1%


## **Fiscal Fourth-Quarter Financial Results**

Adjusted Earnings Per Share Increase 31% Over Q4 FY2017

	(	GAAP Results			A	djusted Res	sults
	4Q18	4Q17 (Restated)	YoY Growth		4Q18	4Q17 (Restated)	YoY Growth
Total Revenue	\$200.9	\$199.6	0%		\$200.9	\$199.6	0%
Gross Profit	\$155.2	\$157.1	(1%)		\$158.0	\$157.1	1%
Gross Margin	77.3%	78.7%	-140 bps		78.6%	78.7%	-10 bps
Operating Income	\$15.9	\$18.9	(16%)		\$34.9	\$27.1	29%
Operating Margin	7.9%	9.5%	-160 bps		17.4%	13.6%	+380 bps
Net Income	\$13.1	\$12.3	7%	-	\$27.6	\$20.2	37%
EPS	\$0.18	\$0.18	0%		\$0.38	\$0.29	31%

### Comparison of Adjusted EPS and FCF/Share

Adjusted EPS Significantly Understates Cash Earnings Power





# FY17 & FY18 Revenue and EPS After Adjustments

#### Revenue (in mil.)

	FY18	FY17 (Restated)	YoY Growth
Q1	\$187.9	\$178.8	5%
Q2	\$192.7	\$196.7	(2%)
Q3	\$191.1	\$194.8	(2%)
Q4	\$200.9	\$199.6	1%
Total	\$772.5	\$769.9	0%

#### **Adjusted EPS**

	FY18	FY17 (Restated)	YoY Growth
Q1	\$0.24	\$0.24	0%
Q2	\$0.30	\$0.24	25%
Q3	\$0.29	\$0.25	16%
Q4	\$0.38	\$0.29	31%
Total	\$1.20	\$1.03	17%

# FY19 Financial Guidance

Metric	Fiscal Year 2019
Revenue	\$880 to \$890 million
GAAP Diluted EPS	\$0.40 to \$0.45
Adjusted EPS	\$1.70 to \$1.75

### FY19 Revenue Guidance Bridge

Overall revenue growth >20% Assuming No Counsyl Synergies

	Fiscal Year 2018 (\$M)		
As Reported	\$772.6		
ASC-606 Impact	(\$28.9)		
Clinic (6 months)	(\$12.7)	Fiscal Year 2019 Guidance	YoY Growth
Post ASC-606, Clinic	\$731.0	\$750-\$760	3% - 4%
Counsyl (11 months)	\$0.0	\$130	NA
Overall	\$731.0	\$880-\$890	20% - 22%

### FY19 Adjusted EPS Guidance Bridge *Adjusted EPS growth > 16%*

	Fiscal Year 2018
Adjusted EPS	\$1.20
Stock Based Compensation	\$0.26
ASC-606 Impact	\$0.01
New Adjusted EPS	\$1.47

# Potential Financial Catalysts in FY19

Multiple Opportunities for Material Upside

Product	Current Status	Initiative	Annualized Financial Impact
GeneSight	6% coverage	Commercial payers, Medicare	Coverage for current contracted payers =
Coverage		and Medicaid coverage	\$67M in rev. and \$0.67 in EPS
GeneSight LCD	Medicare limited to psychiatrists	Revised LCD to include primary care physicians	7% increase in RAM = \$350M potential
Prolaris	55% coverage	Commercial payers	+10% increase in RAM =
Coverage		Medicaid	\$6M in rev. and \$0.06 in EPS
Vectra DA	40% coverage	Commercial payers	+10% increase in RAM =
Coverage		Medicaid	\$7M in rev. and \$0.07 in EPS
myPath Melanoma Coverage	1% coverage	Medicare coverage, additional commercial coverage, sales expansion	Medicare coverage = \$3M in rev. and \$0.03 in EPS
Hereditary Cancer	New indications for 120k patients per year	Expanded indications, riskScore, Met BC	1% incremental YoY volume growth = \$5M in rev. and \$0.05 in EPS
ForeSight Coverage	Limited ECS coverage	Commercial payer coverage for ECS	Medicare price for CPT Code 81412 = \$2,449
Prelude	Average Risk 50%	Commercial payer and Medicaid coverage for average risk	10% increase in Average Risk coverage
Coverage	Medicaid 50%		= \$3M in rev. and \$0.03 in EPS
Reproductive Health	9,000 Myriad OBGYNs	Train Myriad sales force	1 sample/month/MD =
Tests	no calls		\$50M in rev. and \$0.50 in EPS



# 1Q19 Financial Guidance

Metric	First Quarter Fiscal Year 2019
Revenue	\$200 to \$202 million
GAAP Diluted EPS	(\$0.08) to (\$0.06)
Adjusted EPS	\$0.28 to \$0.30

### Hereditary Cancer Upsides in Fiscal Year 2019

Several Significant Contributors to Growth

**Companion Diagnostics** 

- Continued launch of BRACAnalysis CDx in metBC in U.S. and Japan
- BRACAnalysis CDx in firstline ovarian cancer based upon SOLO-1 olaparib data
- Submission of BRACAnalysis CDx in metBC with talazoparib

Indication	Mkt. Expansion				
Prostate Cancer	+40,000				
Pancreatic Cancer	+40,000				
Colon Cancer	+41,000				

Expanded Guidelines

riskScore

- Added validation studies
- New ethnic groups
- Additional clinical data

### **IMPACT Study Published**

Primary Care Physicians Have Even Better Outcomes Than Psychiatrists

Prospective unblinded study


• All 1,871 patients received GeneSight

Clinical Outcome	Primary Care Physicians	Psychiatrists	% Difference	p-value	GUIDED Study Results (Genesight Arm)
Symptom Improvement	31.7%	24.9%	27%	<0.01	27.2%
Response Rates	30.1%	22.3%	35%	<0.01	26.0%
Remission Rates	19.5%	12.0%	63%	<0.01	15.3%

# Self-Insured Employers Another Avenue to Coverage

Comprise 50 Percent of Commercial Lives in the United States


175M Commercial Lives in the U.S.



### Tripling Number of Physician Targets

Guidance Assumes No Contribution From 9,000 Myriad Physicians

37,000 OBGYNs in Clinical Practice




Myriad Oderers Overlap Counsyl Orderers Not Targeted

# Significant Expansion in Prolaris Reimbursement

8 Commercial Payers Now Cover the Test Totaling 20 Million Lives

#### **U.S. Prolaris Insurance Coverage (55%)**



Medicare Private Covered Private Non-Covered Medicare Non-Covered

### Worldwide Leader in Personalized Medicine

- We are entering the golden age for personalized medicine
- Molecular diagnostics are the keystone for improving patient outcomes while eliminating waste in healthcare spending
- Myriad is the pioneer of "research-based" and "education-centric" business model for molecular diagnostics
- We are the best positioned company to lead this revolution in healthcare

